Verge Labs launches vBx-1.0, a virtual biopsy model for neurology
The model predicts brain activity and therapy response with up to 3x greater accuracy, aiming to reduce clinical trial failures.
See the latest news and media coverage for Verge. We track all announcements, press releases, and industry mentions in real time, all in one place.
Artificial intelligence platform for precision neurology drug development
vergelabs.comLast updated
In short: Verge rebranded as Verge Labs, launched virtual biopsy model, and pivoted to partnerships after ALS trial failed.
The model predicts brain activity and therapy response with up to 3x greater accuracy, aiming to reduce clinical trial failures.
Verge will apply its AI platform and human tissue data to characterize targets for Tenacia's CNS programs.
It will open its CONVERGE platform to other drug developers and build a world model to predict patient responses from blood draws.
The partnership leverages Verge's CONVERGE platform, integrating genomics, ML, and disease modeling for drug discovery. Full press release available at Devano.ai.
As the saying goes, one man’s trash is another man’s treasure. Or as Verge Labs might put it, one company’s failed clinical ...
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to ...
Verge Genomics' sole clinical-stage drug has failed, and the California biotech will shift to a partnership model for its AI-driven discovery platform, Endpoints News has...
Verge Genomics Online Auction opens Oct. 21st @ 10am PST BioTek Cytation 5 Imaging Reader w/ BioSpa 8 Automated Incubator Cytiva Luminescent Image Analyzer Model...
Track Verge and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Verge and other trending companies.